Free Trial
→ I have publicly predicted six major American crashes, before each one happened. (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$1.51
$1.49
$0.20
▼
$2.63
$10.35M1.58352,864 shsN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
$1.95
+3.2%		$2.12
$1.79
▼
$5.18
$39.76M0.33101,457 shs109,289 shs
RYTHM, Inc. stock logo
RYM
RYTHM
$18.40
+1.2%		$21.76
$14.00
▼
$53.65
$39.62M9.4612,809 shs24,155 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.91
-1.3%		$4.85
$3.53
▼
$9.12
$39.40M1.06555,326 shs69,669 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.00%0.00%0.00%0.00%0.00%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
+3.17%-4.41%-12.56%-21.05%-37.30%
RYTHM, Inc. stock logo
RYM
RYTHM
-0.04%-5.74%-14.99%-15.52%-60.72%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-1.26%-7.35%-10.93%-8.43%-39.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$1.51
$1.49
$0.20
▼
$2.63
$10.35M1.58352,864 shsN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
$1.95
+3.2%		$2.12
$1.79
▼
$5.18
$39.76M0.33101,457 shs109,289 shs
RYTHM, Inc. stock logo
RYM
RYTHM
$18.40
+1.2%		$21.76
$14.00
▼
$53.65
$39.62M9.4612,809 shs24,155 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.91
-1.3%		$4.85
$3.53
▼
$9.12
$39.40M1.06555,326 shs69,669 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.00%0.00%0.00%0.00%0.00%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
+3.17%-4.41%-12.56%-21.05%-37.30%
RYTHM, Inc. stock logo
RYM
RYTHM
-0.04%-5.74%-14.99%-15.52%-60.72%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-1.26%-7.35%-10.93%-8.43%-39.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.00
N/AN/AN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
2.00
Hold$6.00207.69% Upside
RYTHM, Inc. stock logo
RYM
RYTHM
1.00
SellN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
2.33
Hold$33.00743.99% Upside

Current Analyst Ratings Breakdown

Latest AGRX, GRCE, RYM, and SCYX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
RYTHM, Inc. stock logo
RYM
RYTHM
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
8/13/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$24.00 ➝ $33.00
8/3/2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold
7/31/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
7/24/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$19.98M0.52N/AN/A($5.51) per share-0.27
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/A$3.99 per shareN/A
RYTHM, Inc. stock logo
RYM
RYTHM
$17.28M2.32N/AN/A$6.06 per share3.04
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$20.60M1.89N/AN/A$9.07 per share0.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
-$14.47M-$3.65N/AN/AN/A-36.24%N/A-147.37%N/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$7.79M-$1.18N/AN/AN/AN/A-36.11%-34.39%11/12/2026 (Estimated)
RYTHM, Inc. stock logo
RYM
RYTHM
-$33.26M-$10.53N/AN/AN/A-6.20%-12.57%-2.60%N/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$8.61M-$2.09N/AN/AN/AN/A-44.15%-32.61%11/4/2026 (Estimated)

Latest AGRX, GRCE, RYM, and SCYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q2 2027
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$0.15N/AN/AN/A$1.00 millionN/A
11/4/2026Q3 2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.72N/AN/AN/A$0.13 millionN/A
8/14/2026Q1 2027
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$0.1293-$0.91-$0.7807-$0.91$0.40 millionN/A
8/10/2026Q2 2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.5067$0.63+$1.1367$0.63$0.08 million$0.24 million
8/4/2026Q2 2026
RYTHM, Inc. stock logo
RYM
RYTHM
N/A$0.09N/A$0.09N/A$23.02 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/AN/AN/AN/AN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/AN/A
RYTHM, Inc. stock logo
RYM
RYTHM
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/A
0.56
0.38
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A
11.47
11.47
RYTHM, Inc. stock logo
RYM
RYTHM
N/A
0.59
0.56
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
9.65
9.65

Institutional Ownership

CompanyInstitutional Ownership
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
10.92%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
6.08%
RYTHM, Inc. stock logo
RYM
RYTHM
5.98%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.50%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
10.84%
RYTHM, Inc. stock logo
RYM
RYTHM
3.48%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
306.86 million6.82 millionNot Optionable
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
521.04 million18.76 millionN/A
RYTHM, Inc. stock logo
RYM
RYTHM
1412.18 million2.10 millionN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
299.95 million9.54 millionOptionable

Recent News About These Companies

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease
October 7, 2026  |  marketscreener.comM
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
October 7, 2026  |  defenseworld.netD
SCYNEXIS (NASDAQ:SCYX) Shares Cross Above Fifty Day Moving Average - What's Next?
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31094633
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-scynexis-nasdaq-scyx-stock-price-crosses-above-fifty-day-moving-average-time-to-sell-2026-10-07/
SCYNEXIS Reports Favorable Phase 1 Results For ADPKD Drug
October 6, 2026  |  rttnews.comhttps://www.rttnews.com/3696850/scynexis-reports-favorable-phase-1-results-for-adpkd-drug.aspx
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease ...
October 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scynexis-announces-phase-1-study-results-for-scy-770-a-novel-highly-selective-oral-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-1036600549
SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026
October 6, 2026  |  quiverquant.comQ
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375347/0/en/scynexis-announces-phase-1-study-results-for-scy-770-a-novel-highly-selective-oral-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd.html
SCYNEXIS Secures BARDA Funding for Antifungal Pipeline
September 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SCYX/pressreleases/4866303/scynexis-secures-barda-funding-for-antifungal-pipeline/
SCYNEXIS Secures BARDA Funding for Antifungal Pipeline
September 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SCYX/pressreleases/4866303/scynexis-secures-barda-funding-for-antifungal-pipeline/
Scynexis stock surges on $214M BARDA contract for SCY-247
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scynexis-stock-surges-214m-barda-135830821.html
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scynexis-shares-rise-13-9-121017917.html
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
September 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/28/3369788/0/en/scynexis-awarded-barda-contract-providing-up-to-214-million-in-non-dilutive-funding-for-the-development-of-scy-247.html
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
September 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scynexis-appoints-seasoned-industry-veteran-steven-k-burke-m-d-to-its-board-of-directors-1036563490
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366246/0/en/scynexis-appoints-seasoned-industry-veteran-steven-k-burke-m-d-to-its-board-of-directors.html
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362033/0/en/scynexis-appoints-todd-minga-m-d-as-senior-vice-president-research-development.html
SCYNEXIS Names Sanjay Subramanian as CFO
September 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scynexis-names-sanjay-subramanian-cfo-125711695.html
Scynexis Names Sanjay Subramanian CFO
September 10, 2026  |  rttnews.comhttps://www.rttnews.com/3690011/scynexis-names-sanjay-subramanian-cfo.aspx
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359427/0/en/scynexis-announces-appointment-of-sanjay-subramanian-as-chief-financial-officer.html
SCYNEXIS to Participate in Upcoming Investor Conferences
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354140/0/en/scynexis-to-participate-in-upcoming-investor-conferences.html
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3351035/0/en/scynexis-announces-inducement-award-under-nasdaq-listing-rule-5635-c-4.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agile Therapeutics stock logo

Agile Therapeutics NASDAQ:AGRX

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Grace Therapeutics stock logo

Grace Therapeutics NASDAQ:GRCE

$1.95 +0.06 (+3.17%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$1.94 0.00 (-0.26%)
As of 10/15/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

RYTHM stock logo

RYTHM NASDAQ:RYM

$18.40 +0.22 (+1.21%)
Closing price 10/15/2026 03:58 PM Eastern
Extended Trading
$19.27 +0.87 (+4.71%)
As of 10/15/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$3.91 -0.05 (-1.26%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$3.86 -0.05 (-1.25%)
As of 10/15/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas